Announced details
The life sciences market, including the field of regenerative medicine
The parties entered into a location agreement concerning the establishment of the new plant. Capital and personnel relationships are not disclosed.
Nagasaki Prefecture and Omura City. Other information, including their locations, representatives and business activities, is not disclosed.
1723-1 Ogahara-cho, Omura City (Section 1, the Second Omura High-Tech Park)
The impact of construction of the new plant on consolidated financial results for the current fiscal year is expected to be immaterial.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Cell culture media |
| Counterparty | Nagasaki Prefecture, Omura City |
| Counterparty overview | Nagasaki Prefecture and Omura City. Other information, including their locations, representatives and business activities, is not disclosed. |
| Relationship with the Company | The parties entered into a location agreement concerning the establishment of the new plant. Capital and personnel relationships are not disclosed. |
| Contract Date | 25 August 2026 |
| Launch date | January 2030 (scheduled; the planned opening of the Nagasaki Plant) |
| Applicable area | The life sciences market, including the field of regenerative medicine |
| Location | 1723-1 Ogahara-cho, Omura City (Section 1, the Second Omura High-Tech Park) |
| Location scale | Employment plan: 42 people (new hires and transferees during the 5 years following the opening) |
| Impact on Business Performance | The impact of construction of the new plant on consolidated financial results for the current fiscal year is expected to be immaterial. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company aims to strengthen its stable supply system for cell culture media and respond to growing demand in fields including regenerative medicine. It also intends to expand production capacity, create local employment opportunities and develop human resources.